Difference between revisions of "Vimentin"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
[[Image:Poorly differentiated carcinoma -- vimentin - intermed mag.jpg|thumb|300px|Vimentin staining in a poorly differentiated [[carcinoma]].]] | [[Image:Poorly differentiated carcinoma -- vimentin - intermed mag.jpg|thumb|300px|Vimentin staining in a poorly differentiated [[carcinoma]].]] | ||
[[Image:Lymphoma - lung - vimentin -- intermed mag.jpg|thumb|300px|Vimentin staining in a [[lymphoma]].]] | |||
'''Vimentin''' is a common [[immunostain]]. It marks most [[soft tissue lesions]] and [[malignant melanoma]]. It is usually negative in carcinomas. | '''Vimentin''' is a common [[immunostain]]. It marks most [[soft tissue lesions]] and [[malignant melanoma]]. It is usually negative in carcinomas. | ||
Latest revision as of 04:51, 3 August 2016
Vimentin staining in a poorly differentiated carcinoma.
Vimentin staining in a lymphoma.
Vimentin is a common immunostain. It marks most soft tissue lesions and malignant melanoma. It is usually negative in carcinomas.
Positive
Vimentin and cytokeratin positivity
Common tumours:
- Renal cell carcinoma.[4]
- Endometrial carcinoma.[5]
- Ovarian serous carcinoma.[4]
- Papillary thyroid carcinoma.[4]
- Sarcomatoid carcinoma (spindle cell carcinoma).[4]
Rare tumours:
- Synovial sarcoma.[6]
- Rhabdoid tumour.[7]
- Epithelioid sarcoma.[8]
- Epithelioid angiosarcoma.[4]
- Desmoplastic small round cell tumour.[4]
- Anaplastic thyroid carcinoma.[4]
- Biphasic malignant mesothelioma.[4]
- Carcinosarcoma.[4]
Common tumours that uncommonly have the pattern:
Negative
- Most carcinomas.
See also
References
- ↑ Mısır, AF.; Durmuşlar, MC.; Zerener, T.; Gün, BD. (Apr 2016). "Primary malignant melanoma.". Saudi Med J 37 (4): 446-9. doi:10.15537/smj.2016.4.15017. PMID 27052289.
- ↑ Domagala, W.; Lasota, J.; Chosia, M.; Weber, K.; Osborn, M. (Feb 1989). "Leukocyte-common antigen and vimentin are reliable adjuncts in the diagnosis of non-Hodgkin's lymphoma in fine needle aspirates.". Anal Quant Cytol Histol 11 (1): 15-21. PMID 2524200.
- ↑ Gustmann, C.; Altmannsberger, M.; Osborn, M.; Griesser, H.; Feller, AC. (Jun 1991). "Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas.". Am J Pathol 138 (6): 1413-22. PMID 1711289.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Bahrami, A.; Truong, LD.; Ro, JY. (Mar 2008). "Undifferentiated tumor: true identity by immunohistochemistry.". Arch Pathol Lab Med 132 (3): 326-48. doi:10.1043/1543-2165(2008)132[326:UTTIBI]2.0.CO;2. PMID 18318577.
- ↑ Alkushi, A.; Irving, J.; Hsu, F.; Dupuis, B.; Liu, CL.; Rijn, M.; Gilks, CB. (Mar 2003). "Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.". Virchows Arch 442 (3): 271-7. doi:10.1007/s00428-002-0752-4. PMID 12647218.
- ↑ Llombart-Bosch A, Lopez-Guerrero JA, Peydro-Olaya A (2002). "Synovial sarcoma (SS): new perspectives supported by modern technology". Arkh. Patol. 64 (3): 39–47. PMID 15338724.
- ↑ Itakura E, Tamiya S, Morita K, et al. (September 2001). "Subcellular distribution of cytokeratin and vimentin in malignant rhabdoid tumor: three-dimensional imaging with confocal laser scanning microscopy and double immunofluorescence". Mod. Pathol. 14 (9): 854–61. doi:10.1038/modpathol.3880401. PMID 11557780. http://www.nature.com/modpathol/journal/v14/n9/full/3880401a.html.
- ↑ Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF (August 1999). "Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis". Hum. Pathol. 30 (8): 934–42. PMID 10452506.
- ↑ URL: http://cat.inist.fr/?aModele=afficheN&cpsidt=2504165. Accessed on: 26 April 2011.